Bristol-Myers Squibb (NYSE:BMY) Shares Bought by Joel Isaacson & Co. LLC

Joel Isaacson & Co. LLC raised its position in Bristol-Myers Squibb (NYSE:BMY) by 8.4% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 26,964 shares of the biopharmaceutical company’s stock after acquiring an additional 2,092 shares during the period. Joel Isaacson & Co. LLC’s holdings in Bristol-Myers Squibb were worth $1,395,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Legacy Wealth Asset Management LLC grew its stake in Bristol-Myers Squibb by 2.1% during the 3rd quarter. Legacy Wealth Asset Management LLC now owns 10,288 shares of the biopharmaceutical company’s stock valued at $532,000 after purchasing an additional 215 shares during the last quarter. Pettinga Financial Advisors LLC increased its holdings in Bristol-Myers Squibb by 8.7% in the 3rd quarter. Pettinga Financial Advisors LLC now owns 11,108 shares of the biopharmaceutical company’s stock worth $575,000 after buying an additional 886 shares during the period. Mediolanum International Funds Ltd raised its position in Bristol-Myers Squibb by 0.5% during the 3rd quarter. Mediolanum International Funds Ltd now owns 88,527 shares of the biopharmaceutical company’s stock worth $4,499,000 after buying an additional 484 shares during the last quarter. Lake Street Advisors Group LLC lifted its stake in Bristol-Myers Squibb by 22.3% during the 3rd quarter. Lake Street Advisors Group LLC now owns 12,224 shares of the biopharmaceutical company’s stock valued at $632,000 after acquiring an additional 2,227 shares during the period. Finally, Hudock Inc. boosted its holdings in shares of Bristol-Myers Squibb by 7.5% in the 3rd quarter. Hudock Inc. now owns 5,819 shares of the biopharmaceutical company’s stock valued at $301,000 after acquiring an additional 408 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BMY has been the subject of a number of research reports. Sanford C. Bernstein initiated coverage on shares of Bristol-Myers Squibb in a research report on Thursday, October 17th. They set a “market perform” rating and a $56.00 target price for the company. Citigroup downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $75.00 to $55.00 in a research note on Friday. Jefferies Financial Group lifted their price target on Bristol-Myers Squibb from $49.00 to $51.00 and gave the company a “hold” rating in a research report on Wednesday, August 28th. Deutsche Bank Aktiengesellschaft lowered their price objective on Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating on the stock in a research report on Tuesday, July 23rd. Finally, UBS Group boosted their target price on shares of Bristol-Myers Squibb from $50.00 to $54.00 and gave the company a “neutral” rating in a research note on Wednesday, October 9th. Two research analysts have rated the stock with a sell rating, fifteen have given a hold rating, one has given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $53.31.

Bristol-Myers Squibb Price Performance

Shares of Bristol-Myers Squibb stock opened at $51.92 on Friday. The business has a 50 day simple moving average of $50.70 and a two-hundred day simple moving average of $46.44. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $55.29. The stock has a market capitalization of $105.24 billion, a P/E ratio of -16.75, a PEG ratio of 13.75 and a beta of 0.46. The company has a debt-to-equity ratio of 2.86, a current ratio of 1.16 and a quick ratio of 1.02.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Friday, July 26th. The biopharmaceutical company reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $1.64 by $0.43. Bristol-Myers Squibb had a positive return on equity of 12.51% and a negative net margin of 14.06%. The business had revenue of $12.20 billion during the quarter, compared to analysts’ expectations of $11.54 billion. During the same quarter in the prior year, the firm earned $1.75 earnings per share. The business’s revenue was up 8.7% compared to the same quarter last year. As a group, analysts predict that Bristol-Myers Squibb will post 0.77 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, November 1st. Shareholders of record on Friday, October 4th will be issued a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.62%. Bristol-Myers Squibb’s payout ratio is currently -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.